IMS Health news from FierceBiotech
NewsBiotech drug sales grow 12.5% in 2007
Pharmaceuticals may be struggling, but biotech drugs are on fire. According to an IMS Health study, global sales of biotech drugs increased 12.5 percent in 2007 to more than $75 billion; that's twice Read more...
SPOTLIGHT: Pace of outsourcing accelerating, IMS says
Drugmakers are pulling out of manufacturing at an unprecedented rate, according to a new report from IMS Health. Four of the top 10 pharma players announced big new outsourcing programs last year. Read more...
ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
> Ambrilia Biopharma reported positive 24-week Phase III top-line results for prolonged-release formulation of Octreotide. Read more...
ALSO NOTED: Acadia reports positive psychosis data; Alcon drug gets approval; FDA green lights migraine drug; and much more...
> Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
SPOTLIGHT: Pharma growth drops to 1961 levels
IMS Health is out with its new annual pharma sales report, and it's not pretty. Revenue grew by only 3.8 percent to $286.5 billion, the slowest pace of expansion since 1961. By contrast, sales Read more...
ALSO NOTED: Lentigen moves to Gaithersburg; Acorda prices shares; Cytheris releases data; and much more...
> Lentigen Corporation today announced the company is moving its corporate headquarters and manufacturing facilities from the University of Maryland Baltimore County TechCenter to a new 26,000 Read more...
ALSO NOTED: Osiris inks $224M contract; Baxter and Nektar to collaborate;and much more...
> Osiris Therapeutics has inked a deal with the U.S. Defense Department to supply a potential $224 million worth of Prochymal for use in treating military personnel exposed to radiation. Read more...
ALSO NOTED: Sucampo Pharma names new CEO; Genetic tests are going DTC at a fast pace; Panel: Give FDA power to recall; and much
> Teva and the Technion Israel Institute of Technology are exploring a pact to develop stem cell lines for research work. Read more...
ALSO NOTED: Pharma growth sinking to historic low; Neurocrine gains Japanese partner; OccuLogix suspends development program;an
> Here's statistical confirmation of the gloom-and-doom facing Big Pharma. Worldwide sales growth will Read more...
| Press ReleasesPRESS RELEASE: IMS Health, Wolters Kluwer Health and Verispan Challenge State Laws IMS Health, Wolters Kluwer Health and Verispan Challenge State Laws Restricting Access to Critical Healthcare Information Prescribing Information Vital to Improving Healthcare Quality and Patient Read more... |
Get more IMS Health coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends